Quectel Breaks Ground for New Innovation Headquarters and Readies for Aggressive Growth Plans With Opening of Most Advanced Smart Factory
16.5.2023 19:25:00 EEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, today announces breaking ground for its new innovation Headquarter in Shanghai and also recently celebrated a significant milestone with the opening of its new Global Intelligent Manufacturing Center (GIMC) in Changzhou.
Delivering advanced IoT automation, the new GIMC facility features a fully functioning manufacturing production line that combines latest technologies, including edge intelligence, machine learning, robotics and machine vision solutions built with Quectel’s latest smart module technologies which significantly expands manufacturing capabilities to guarantee supply and reassure product quality for global customers. Designed and architected by a group of its own IoT experts, this state-of-the art IoT manufacturing center is equipped with the most advanced industrial automation technologies including:
- Fully automated warehouse storage system with 65,000 material cubicles, which can support 40 SMT lines material supply and operate 7x24 based on real-time workorders.
- End-to-end touchless process with Automatic Guided Vehicles to transport raw material to production lines, hand-over semi-products from SMT for testing and final packing with minimal manpower.
- 30 Fuji NXT-III SMT lines with Siemens MES monitoring system supporting production of up to 150 million modules per year.
- 85 Quectel Self Design Automatic Testing Stations with full testing log files onto each module produced.
- 40 Quectel Self Design Auto Inspection and Packing Systems.
The GIMC project started construction in September 2021 and will commence operation in 2023. The smart factory will further enhance Quectel’s production capabilities, strengthening its core competitiveness. The center occupies an area of 72,000 square meters, with a total construction space of 160,000 square meters. It is capable of manufacturing Quectel’s full range of modules, including 4G modules, 5G modules, smart modules, automotive grade modules, narrowband IoT modules, GNSS modules, Wi-Fi modules and antennas.
“Our new smart factory represents an important step toward the next generation of smart manufacturing and will guarantee both our product quality and production capacity, sufficient to meet various demanding requirements of our global customers,” said Patrick Qian, CEO of Quectel. “Applying IoT innovation to our own processes -- will not only help us enhance our industry leading quality -- it will also accelerate the expansion of the global IoT market and be a catalyst for the entire IoT eco-system.”
Quectel also recently broke ground for its new headquarters in Shanghai. “The new headquarter is designed to provide a modern, smart environment that makes it attractive for the best people to work, excel and innovate and that exceeds the highest standards in sustainability, health and wellness,” Mr. Qian continued.” It will host Quectel’s R&D center and IoT innovation showroom and will bring together some of the world’s greatest engineers and IoT leaders to accelerate innovation and drive the future of IoT”. The new headquarter of approximately 100,000 square meters will serve as a central hub for administrative and research and development functions but will also offer a wide range of amenities including sports facilities, conference spaces, outdoor gardens, catering services, and ample parking facilities. The company plans to officially inaugurate and begin operations at the new headquarters in 2025.
Founded in 2010, Quectel has consistently maintained rapid development and has become a leading global IoT provider of solutions covering cellular modules, Wi-Fi modules, smart modules, automotive modules, GNSS modules, antennas as well as connectivity and certification services.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 6,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas, services and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005801/en/
Contact information
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom